306 related articles for article (PubMed ID: 37261958)
1. Reevaluating the Role of Progesterone in Ovarian Cancer: Is Progesterone Always Protective?
Mauro LJ; Spartz A; Austin JR; Lange CA
Endocr Rev; 2023 Nov; 44(6):1029-1046. PubMed ID: 37261958
[TBL] [Abstract][Full Text] [Related]
2. Navigating a plethora of progesterone receptors: Comments on the safety/risk of progesterone supplementation in women with a history of breast cancer or at high-risk for developing breast cancer.
Diep CH; Mauro LJ; Lange CA
Steroids; 2023 Dec; 200():109329. PubMed ID: 37884178
[TBL] [Abstract][Full Text] [Related]
3. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
4. Progesterone action in breast, uterine, and ovarian cancers.
Diep CH; Daniel AR; Mauro LJ; Knutson TP; Lange CA
J Mol Endocrinol; 2015 Apr; 54(2):R31-53. PubMed ID: 25587053
[TBL] [Abstract][Full Text] [Related]
5. Progesterone Receptors Promote Quiescence and Ovarian Cancer Cell Phenotypes via DREAM in p53-Mutant Fallopian Tube Models.
Mauro LJ; Seibel MI; Diep CH; Spartz A; Perez Kerkvliet C; Singhal H; Swisher EM; Schwartz LE; Drapkin R; Saini S; Sesay F; Litovchick L; Lange CA
J Clin Endocrinol Metab; 2021 Jun; 106(7):1929-1955. PubMed ID: 33755733
[TBL] [Abstract][Full Text] [Related]
6. Promotion of BRCA1-associated triple-negative breast cancer by ovarian hormones.
Lee EY
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):68-73. PubMed ID: 18197009
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania.
Janavičius R; Rudaitis V; Mickys U; Elsakov P; Griškevičius L
Cancer Genet; 2014 May; 207(5):195-205. PubMed ID: 25066507
[TBL] [Abstract][Full Text] [Related]
8. The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.
Widschwendter M; Rosenthal AN; Philpott S; Rizzuto I; Fraser L; Hayward J; Intermaggio MP; Edlund CK; Ramus SJ; Gayther SA; Dubeau L; Fourkala EO; Zaikin A; Menon U; Jacobs IJ
Lancet Oncol; 2013 Nov; 14(12):1226-32. PubMed ID: 24140203
[TBL] [Abstract][Full Text] [Related]
9. The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?
Teixeira N; van der Hout A; Oosterwijk JC; Vos JR; ; Devilee P; van Engelen K; Meijers-Heijboer H; van der Luijt RB; Kriege M; Mensenkamp AR; Rookus MA; van Roozendaal KE; Mourits MJE; de Bock GH
Eur J Hum Genet; 2018 Jun; 26(6):848-857. PubMed ID: 29483665
[TBL] [Abstract][Full Text] [Related]
10. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
Sokolenko AP; Sokolova TN; Ni VI; Preobrazhenskaya EV; Iyevleva AG; Aleksakhina SN; Romanko AA; Bessonov AA; Gorodnova TV; Anisimova EI; Savonevich EL; Bizin IV; Stepanov IA; Krivorotko PV; Berlev IV; Belyaev AM; Togo AV; Imyanitov EN
Breast Cancer Res Treat; 2020 Nov; 184(1):229-235. PubMed ID: 32776218
[TBL] [Abstract][Full Text] [Related]
11. Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA
Ponandai-Srinivasan S; Lalitkumar PG; Garcia L; Varghese SJ; Carlson JW; Gemzell-Danielsson K; Floter Radestad A
Acta Obstet Gynecol Scand; 2019 Feb; 98(2):250-261. PubMed ID: 30325501
[TBL] [Abstract][Full Text] [Related]
12. Cell type-specific genotoxicity in estrogen-exposed ovarian and fallopian epithelium.
Song L; Tang Z; Peng C; Yang Y; Guo C; Wang D; Guo L; Chen J; Liu C
BMC Cancer; 2020 Oct; 20(1):1020. PubMed ID: 33087072
[TBL] [Abstract][Full Text] [Related]
13. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
Li A; Xie R; Zhi Q; Deng Y; Wu Y; Li W; Yang L; Jiao Z; Luo J; Zi Y; Sun G; Zhang J; Shi Y; Liu J
Gynecol Oncol; 2018 Oct; 151(1):145-152. PubMed ID: 30078507
[TBL] [Abstract][Full Text] [Related]
14. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
Kotsopoulos J; Gronwald J; Karlan B; Rosen B; Huzarski T; Moller P; Lynch HT; Singer CF; Senter L; Neuhausen SL; Tung N; Eisen A; Foulkes WD; Ainsworth P; Sun P; Lubinski J; Narod SA;
Gynecol Oncol; 2018 Jul; 150(1):85-91. PubMed ID: 29793803
[TBL] [Abstract][Full Text] [Related]
15. Challenges to defining a role for progesterone in breast cancer.
Lange CA
Steroids; 2008 Oct; 73(9-10):914-21. PubMed ID: 18243264
[TBL] [Abstract][Full Text] [Related]
16. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study.
Antoniou AC; Rookus M; Andrieu N; Brohet R; Chang-Claude J; Peock S; Cook M; Evans DG; Eeles R; ; Nogues C; Faivre L; Gesta P; ; van Leeuwen FE; Ausems MG; Osorio A; ; Caldes T; Simard J; Lubinski J; Gerdes AM; Olah E; Fürhauser C; Olsson H; Arver B; Radice P; Easton DF; Goldgar DE
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):601-10. PubMed ID: 19190154
[TBL] [Abstract][Full Text] [Related]
17. The pill and the breast.
Drife JO
IPPF Med Bull; 1984 Dec; 18(6):1-2. PubMed ID: 12313402
[TBL] [Abstract][Full Text] [Related]
18. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters.
Calvo V; Beato M
Cancer Res; 2011 May; 71(9):3422-31. PubMed ID: 21531767
[TBL] [Abstract][Full Text] [Related]
20. Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence.
de Juan Jiménez I; García Casado Z; Palanca Suela S; Esteban Cardeñosa E; López Guerrero JA; Segura Huerta Á; Chirivella González I; Sánchez Heras AB; Juan Fita MJ; Tena García I; Guillen Ponce C; Martínez de Dueñas E; Romero Noguera I; Salas Trejo D; Goicoechea Sáez M; Bolufer Gilabert P
Fam Cancer; 2013 Dec; 12(4):767-77. PubMed ID: 23479189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
